Clinical and etiological analysis of co‐infections and secondary infections in COVID‐19 patients: An observational study

• DOI: 10.1111/crj.13369
• Publication Date: 2021-04-05T15:14:56Z
• Authors: Shuyan Chen; Qing Zhu; Yanyu Xiao; Chi Wu; Zhaofang Jiang; Lei Liu; Jiuxin Qu
• Keywords: Procalcitonin; Etiology

Co-infections, secondary bacterial or fungal infections, are important risk factors for poor outcomes in viral infections. The prevalence of co-infection and infection patients infected with SARS-CoV-2 is not well understood.To investigate the role co-infections infections disease severity hospitalized individuals COVID-19.A retrospective study was carried out between 11 January 2020 1 March among 408 laboratory confirmed COVID-19 China. These were divided into three groups based on severity: mild moderate, severe, critically ill. Microbiological pathogens blood, urine, respiratory tract specimens detected by combination culture, serology, polymerase chain reaction, metagenomic next-generation sequencing (mNGS).The median age participants 48 years (IQR 34-60 years). Fifty-two (12.7%) had at least one additional pathogen, 8.1% co-infected, 5.1% a infection. There 13 Mycoplasma pneumoniae cases, 8 Haemophilus influenzae viruses, 3 Streptococcus primarily moderate patients. Hospital-acquired more common ill Compared to those without pathogens, and/or likely receive antibiotics (p < 0.001) have elevated levels d-dimer = 0.0012), interleukin-6 0.0027), procalcitonin 0.0002). performance conventional culture comparable that mNGS diagnosis infections.Co-infections existed relevant severity. Screening hospital control should be strengthened.